Commodore Capital
Latest statistics and disclosures from Commodore Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MRUS, VERA, XENE, PCVX, ELVN, and represent 37.05% of Commodore Capital's stock portfolio.
- Added to shares of these 10 stocks: ALKS (+$43M), NRIX (+$37M), Oruka Therapeutics (+$34M), CNTA (+$22M), TIL (+$10M), MRUS (+$7.5M), CLDX (+$6.6M), MNMD, AVTX, KURA.
- Started 4 new stock positions in CNTA, Oruka Therapeutics, NRIX, TIL.
- Reduced shares in these 10 stocks: NUVL (-$56M), PCVX (-$44M), RYTM (-$30M), COGT (-$24M), IMVT (-$20M), CATX (-$18M), ARVN (-$17M), SLNO (-$8.3M), AUTL, THRD.
- Sold out of its positions in ABIO, AUTL, IMVT.
- Commodore Capital was a net seller of stock by $-45M.
- Commodore Capital has $1.6B in assets under management (AUM), dropping by 9.23%.
- Central Index Key (CIK): 0001831942
Tip: Access up to 7 years of quarterly data
Positions held by Commodore Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Commodore Capital
Commodore Capital holds 36 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Merus N V (MRUS) | 10.5 | $167M | +4% | 3.4M | 49.96 |
|
| Vera Therapeutics Cl A (VERA) | 6.8 | $109M | 2.5M | 44.20 |
|
|
| Xenon Pharmaceuticals (XENE) | 6.6 | $106M | 2.7M | 39.37 |
|
|
| Vaxcyte (PCVX) | 6.6 | $105M | -29% | 920k | 114.27 |
|
| Enliven Therapeutics (ELVN) | 6.5 | $105M | +3% | 4.1M | 25.54 |
|
| Nuvalent Inc-a (NUVL) | 6.0 | $96M | -36% | 940k | 102.30 |
|
| Cogent Biosciences (COGT) | 5.1 | $81M | -22% | 7.5M | 10.80 |
|
| Alkermes SHS (ALKS) | 5.1 | $81M | +110% | 2.9M | 27.99 |
|
| Soleno Therapeutics (SLNO) | 4.0 | $64M | -11% | 1.3M | 50.49 |
|
| Spyre Therapeutics Com New (SYRE) | 3.7 | $59M | 2.0M | 29.41 |
|
|
| Miragen Therapeutics (VRDN) | 3.6 | $58M | 2.6M | 22.75 |
|
|
| Celldex Therapeutics Com New (CLDX) | 3.4 | $55M | +13% | 1.6M | 33.99 |
|
| Mind Medicine Mindmed Com New (MNMD) | 2.8 | $46M | +11% | 8.0M | 5.69 |
|
| Perspective Therapeutics Com New (CATX) | 2.8 | $45M | -28% | 3.4M | 13.35 |
|
| Nurix Therapeutics (NRIX) | 2.3 | $37M | NEW | 1.7M | 22.47 |
|
| Pharvaris N V (PHVS) | 2.2 | $35M | +5% | 1.9M | 18.52 |
|
| Kura Oncology (KURA) | 2.2 | $35M | +12% | 1.8M | 19.54 |
|
| Rhythm Pharmaceuticals (RYTM) | 2.1 | $34M | -46% | 650k | 52.39 |
|
| Oruka Therapeutics | 2.1 | $34M | NEW | 1.4M | 24.51 |
|
| Arvinas Ord (ARVN) | 1.8 | $30M | -36% | 1.2M | 24.63 |
|
| Celcuity (CELC) | 1.4 | $23M | +3% | 1.5M | 14.91 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.3 | $22M | NEW | 1.4M | 15.99 |
|
| Nkarta (NKTX) | 1.3 | $21M | +12% | 4.7M | 4.52 |
|
| Oric Pharmaceuticals (ORIC) | 1.3 | $21M | 2.0M | 10.25 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 1.2 | $19M | 3.4M | 5.70 |
|
|
| Third Harmonic Bio (THRD) | 1.2 | $18M | -11% | 1.4M | 13.55 |
|
| Syndax Pharmaceuticals (SNDX) | 1.1 | $17M | +7% | 885k | 19.25 |
|
| Apogee Therapeutics (APGE) | 1.1 | $17M | 290k | 58.74 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 0.9 | $15M | 1.3M | 11.52 |
|
|
| Instil Bio Com New (TIL) | 0.6 | $10M | NEW | 151k | 67.32 |
|
| Neurogene (NGNE) | 0.5 | $8.4M | 200k | 41.96 |
|
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.5 | $7.5M | 750k | 10.01 |
|
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.3 | $5.2M | 500k | 10.45 |
|
|
| Cabaletta Bio (CABA) | 0.3 | $5.2M | 1.1M | 4.72 |
|
|
| Vistagen Therapeutics Ord (VTGN) | 0.3 | $4.7M | 1.6M | 3.01 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $4.6M | +1107% | 483k | 9.50 |
|
Past Filings by Commodore Capital
SEC 13F filings are viewable for Commodore Capital going back to 2020
- Commodore Capital 2024 Q3 filed Nov. 14, 2024
- Commodore Capital 2024 Q2 filed Aug. 14, 2024
- Commodore Capital 2024 Q1 filed May 15, 2024
- Commodore Capital 2023 Q4 filed Feb. 14, 2024
- Commodore Capital 2023 Q4 restated filed Feb. 14, 2024
- Commodore Capital 2023 Q3 filed Nov. 14, 2023
- Commodore Capital 2023 Q2 filed Aug. 14, 2023
- Commodore Capital 2023 Q1 filed May 15, 2023
- Commodore Capital 2022 Q4 filed Feb. 14, 2023
- Commodore Capital 2022 Q3 filed Nov. 14, 2022
- Commodore Capital 2022 Q2 filed Aug. 15, 2022
- Commodore Capital 2022 Q1 filed May 16, 2022
- Commodore Capital 2021 Q4 filed Feb. 14, 2022
- Commodore Capital 2021 Q3 filed Nov. 15, 2021
- Commodore Capital 2021 Q1 restated filed Oct. 14, 2021
- Commodore Capital 2021 Q2 restated filed Oct. 14, 2021